Loading company
ONCBeone Medicines Ltd.$47.6BA+Built from Cognition Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Cognition Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
$0.67-1.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Not rated
The band under the price shows the grade on each date, built only from filings that were public by then.
There is no grade history to chart for Cognition Therapeutics, Inc. yet. The quarterly grade is rebuilt from only the filings that were public at the time, and this company has not yet reported enough of them to score a single quarter.
